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Prevalence of rheumatoid arthritis in 
low– and middle–income countries: A 
systematic review and analysis
Background Rheumatoid arthritis (RA) is an autoimmune disorder 
that affects the small joints of the body. It is one of the leading causes 
of chronic morbidity in high–income countries, but little is known 
about the burden of this disease in low– and middle–income coun-
tries (LMIC).
Methods The aim of this study was to estimate the prevalence of RA 
in six of the World Health Organization's (WHO) regions that har-
bour LMIC by identifying all relevant studies in those regions. To 
accomplish this aim various bibliographic databases were searched: 
PubMed, EMBASE, Global Health, LILACS and the Chinese data-
bases CNKI and WanFang. Studies were selected based on pre–de-
fined inclusion criteria, including a definition of RA based on the 
1987 revision of the American College of Rheumatology (ACR) def-
inition.
Results Meta–estimates of regional RA prevalence rates for countries 
of low or middle income were 0.40% (95% CI: 0.23–0.57%) for 
Southeast Asian, 0.37% (95% CI: 0.23–0.51%) for Eastern Mediter-
ranean, 0.62% (95% CI: 0.47–0.77%) for European, 1.25% (95% 
CI: 0.64–1.86%) for American and 0.42% (95% CI: 0.30–0.53%) 
for Western Pacific regions. A formal meta–analysis could not be per-
formed for the sub–Saharan African region due to limited data. Male 
prevalence of RA in LMIC was 0.16% (95% CI: 0.11–0.20%) while 
the prevalence in women reached 0.75% (95% CI: 0.60–0.90%). 
This difference between males and females was statistically signifi-
cant (P < 0.0001). The prevalence of RA did not differ significantly 
between urban and rural settings (P = 0.353). These prevalence esti-
mates represent 2.60 (95% CI: 1.85–3.34%) million male sufferers 
and 12.21 (95% CI: 9.78–14.67%) million female sufferers in LMIC 
in the year 2000, and 3.16 (95% CI: 2.25–4.05%) million affected 
males and 14.87 (95% CI: 11.91–17.86%) million affected females 
in LMIC in the year 2010.
Conclusion Given that majority of the world’s population resides in 
LMIC, the number of affected people is substantial, with a projection 
to increase in the coming years. Therefore, policy makers and health–
care providers need to plan to address a significant disease burden 
both socially and economically.
Electronic supplementary material:  
The online version of this article contains supplementary material.
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In recent years there has been a shift in diseases and health 
related challenges that the world is facing. Non–commu-
nicable diseases (NCD) have emerged as the leading cause 
of death worldwide, accounting for two–thirds of all deaths 
and deaths are projected to increase in the coming years 
[1]. Contrary to popular belief, these diseases are not lim-
ited to the developed world; they are increasingly prevalent 
in low– and middle–income countries (LMIC), which are 
facing the double burden of both communicable and non–
communicable diseases [2]. In LMIC, constrained health 
care facilities, lack of resources and funds at individual and 
national level lead to limited treatment and support for 
NCD, which mainly affect the working age population with 
a negative impact on household incomes and equity. The 
high burden of NCD poses additional problems for LMIC, 
creating a vicious cycle by worsening poverty that in turn 
results in a further rise of NCD [1]. Acknowledgment of 
the serious implications of the global burden of NCD has 
led to an international response. The United Nations (UN) 
High–level meeting on NCD in 2011 addressed these is-
sues and has paved the way for tackling them, by provid-
ing guidance on how to strengthen national capacities to 
address NCD and integrate prevention and control activi-
ties across sectors and at all levels of governance and 
health–care provision in LMIC [1,2].
While there is wide recognition of the four main NCD with 
a major contribution to the global burden – cardiovascular 
diseases, cancers, diabetes mellitus and chronic respiratory 
illnesses [2] – there are a large number of other NCD that 
cause extensive morbidity, but are neglected as they do not 
significantly contribute to mortality. One such disease is 
rheumatoid arthritis (RA), the most common type of in-
flammatory musculoskeletal disorder [3,4], in which the 
quality of life has been reported to be lower than in patients 
suffering from most of the other NCD [5,6]. It is a chronic 
systematic autoimmune inflammatory disease, character-
ised by a symmetrical persistent synovitis of the joints of 
the hands, wrist, feet and knee resulting in tender swelling 
of joints, pain, limitation in motion and morning stiffness. 
Its systematic features include fatigue, generalised weak-
ness, loss of weight and low grade fever [7]. As the disease 
advances, irreversible tissue damage occurs, with destruc-
tion of bone and cartilage leading to joint deformity, mus-
cle atrophy, and progression that may involve all joints of 
the body [8]. For the purpose of clinical trials, RA is diag-
nosed using the American College of Rheumatology (ACR) 
criteria, formerly known as the American Rheumatology 
Association (ARA) criteria [7,9].
The prevalence of RA in the western world is 1–2% [10], 
and is believed to be 1% worldwide [11]. However, this 
global estimate is based on a few sporadic studies over dif-
ferent time periods, in a limited number of LMIC. Extrapo-
lation from a few studies is problematic given that there is 
ample evidence that RA is a variable disease in time and place 
[11]. Moreover, the burden of NCD has increased over the 
past decade in LMIC, while it has decreased in high–income 
countries [11]. RA also has a substantial economic impact, 
which can be quantified as direct (cost of medication, hos-
pital stay and visits, care–givers and helpers); indirect (loss 
of productivity from absenteeism or early retirement); and 
intangible costs that are measured by the impact on quality 
of life [12,13]. In the United States, the direct cost of RA was 
approximately US$ 13 500 per affected person per year, and 
indirect costs could range between US$ 1000 and US$ 
33 000 per affected person per year [14]. However, not much 
is known about costs in the developing world [13].
This paper aims to provide an estimate for the global and 
regional burden of rheumatoid arthritis by systematically 
reviewing relevant literature in both English databases and 
those in other languages; to study the variation in the prev-
alence of rheumatoid arthritis by gender, region and setting 
(urban/rural); and to discuss the significance of these prev-
alence estimates and their implications for public health 
policy.
METHODS
Definition of population under study and 
literature search
The World Bank database was referenced to compile a list 
of all the LMIC in the world [15]. Thereafter, all LMIC were 
grouped into regions in accordance to the World Health 
Organization (WHO) regions [16]. WHO divides the world 
into six regions; Southeast Asian Region (SEAR), Eastern 
Mediterranean Region (EMR), Western Pacific Region 
(WPR), Europe (EUR), The Americas (AMR) and Sub–Sa-
haran Africa (AFR) [17–19]. A systematic literature search 
was conducted separately for each region to find popula-
tion based studies that documented the prevalence of RA. 
Medline (1946 – July week 1, 2013), EMBASE (1976– 
2013 week 26) and Global Health (GH) (1973 – 2013 
week 26) were searched using the OVID search engine 
(search terms available in Online Supplementary Docu-
ment). Both Medical Subject Headings (MeSH terms) and 
keywords were used in OVID. Other online databases such 
as PubMed, Web of Knowledge (WoK) and databases se-
lective to regions, such as LILACS for Latin America, CNKI 
and Wan Fang for China, and IndMed for India, were also 
thoroughly searched. PubMed was searched for all regions, 
as it proved to be broader and more sensitive in picking up 
studies. Grey literature was also searched for all low–mid-
dle income countries using SIGLE (OpenGrey), Google 
Scholar and Global Health library. The search of grey lit-
erature resulted in 10 and 149 studies, respectively, none 
of which were relevant to this analysis.
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Inclusion and exclusion criteria for study 
selection
After the initial screen, inclusion and exclusion criteria 
were applied to retain only the studies that were free of any 
apparent bias. We included studies conducted in LMIC 
from all WHO regions that were population based or com-
munity based, studies conducted after 1987 that used ARA/
ACR diagnostic criteria (see Table 1), focused on adult 
populations (typically 15+ or 18+ years, with exclusion of 
juvenile forms in the former studies) and reported the prev-
alence rate of RA. We excluded review articles with second-
ary data only (with the exception of sub–Saharan Africa, 
where the amount of data was particularly scarce), hospi-
tal–based studies (for lack of representativeness of the gen-
eral population), studies conducted prior to or during 1987 
(for inconsistent case definition), studies on other types of 
arthritis in adults, studies on juvenile forms of arthritis and 
studies that used other diagnostic criteria to measure the 
prevalence of RA in the population.
We retained studies that clearly presented the method of 
diagnosing RA, beginning with how the sample population 
was recruited and evaluated, along with the criteria used 
for diagnosis of RA. We expected that trained personnel or 
specialists be involved in the field work, and we excluded 
the studies where self–reporting was the primary method 
of case ascertainment. Specialists (doctors, rheumatolo-
gists) needed to be involved in the next step of confirma-
tion. Any study where there was no direct contact between 
the assessors and sample population, such as telephone 
surveys, were excluded. There is a high probability of mis-
classification and oversight of cases by untrained or inad-
equately trained personnel, or through indirect contact.
Figure 1 summarises the process of study selection for all 
six WHO regions. First, duplicates were excluded and titles 
and abstracts of the retained papers were evaluated for rel-
evant studies. Full texts of selected studies were analysed 
and inclusion and exclusion criteria were applied. Data 
from all relevant studies was extracted into an Excel spread-
sheet, where sample size (age, sex–specific, mean age), 
methodology, criteria used for diagnosing RA, study loca-
tion (urban or rural) and prevalence rate were documented 
for each study.
Adjustment of prevalence rates
Once the final set of studies was retained (Figure 1), crude 
prevalence rates, sex–specific prevalence rates, urban and 
rural prevalence rates and male–to–female ratio of RA cas-
es were adjusted to the same measurement unit and ex-
pressed as a percentage. Data extracted from each study is 
shown in the Online Supplementary Document. Checks 
for internal consistency of the data were made and possible 
significant correlations between prevalence rate and the 
sample size, year of publication of the study, sex and resi-
dency were made.
Statistical analyses
All statistical analyses are shown in the Online Supple-
mentary Document. We first tested the distribution of the 
reported prevalence of RA across all identified studies for 
normality using the one–sample Kolmogorov-Smirnov test. 
We concluded that the results did not indicate normal dis-
tribution, presumably because of substantial heterogeneity 
in the included studies (Z = 1.831, P = 0.002). We then per-
formed a meta–analysis of all identified studies in all LMIC 
using the DerSimonian–Laird method, to determine the 
“LMIC” prevalence rate (Online Supplementary Docu-
ment).
We then displayed mean and median prevalences in each 
of the six WHO regions (Figure 2). The Kruskal-Wallis 
Table 1. The criteria of the American College of Rheumatology (ACR) established in 1987 to assist clinical diagnosis of rheumatoid 
arthritis*
1. Morning stiffness Morning stiffness in and around the joints, lasting at least 1 hour before maximal improvement
2. Arthritis of 3 or more joints At least 3 joint areas simultaneously have had soft tissue swelling or fluid (not bony overgrowth alone) observed 
by a physician. The 14 possible areas are right or left PIP, MCP, wrist, elbow, knee, ankle, and MTP joints
3. Arthritis of hand joints At least 1 area swollen (as defined above) in a wrist, MCP, or PIP joint
4. Symmetric arthritis Simultaneous involvement of the same joint areas (as defined in 2) on both sides of the body (bilateral involve-
ment of PIPs, MCPs, or MTPs is acceptable without absolute symmetry
5. Rheumatoid nodules Subcutaneous nodules, over bony prominences, or extensor surfaces, or in juxta–articular regions, observed by a 
physician
6. Serum rheumatoid factor Demonstration of abnormal amounts of serum rheumatoid factor by any method for which the result has been 
positive in <5% of normal control subjects
7. Radiographic changes Radiographic changes typical of rheumatoid arthritis on postero–anterior hand and wrist radiographs, which must 
include erosions or unequivocal bony decalcification localized in or most marked adjacent to the involved joints 
(osteoarthritis changes alone do not qualify
PIP – proximal interphalangeal; MCP – metacarpophalangeal; MTP – metatarsophalangeal
*Four out of the seven criteria need to be met in order to establish the diagnosis of RA, with criteria 1–4 required to be present for at least 6 weeks. Pa-
tients with two clinical diagnoses are not excluded [9].
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one–way analysis of variance by ranks examined whether 
samples originated from the same distribution. After this, 
we conducted a series of region–specific meta–analyses to 
estimate regional prevalence and confidence intervals, us-
ing the DerSimonian–Laird method (Online Supplemen-
tary Document).
An important possible confounding effect was differences in 
the mean age of the sample between the studies. This is be-
cause, although all samples were defined as “adult popula-
tion” (usually 15 years of age or older), the relative contribu-
tion of elderly population varied in different countries 
because of difference in sampling strategies and overall life 
expectancy. We explored the association between the preva-
lence of RA and the mean age using linear correlation coef-
ficients (Pearson, Kendall’s tau, and Spearman), and also the 
generalised dependence measure mutual information to ex-
clude the potential effect of age distribution on generalisabil-
ity of the results (Online Supplementary Document).
Association between gender and prevalence of RA, where 
a considerable difference between sexes was expected, was 
explored using the paired samples t–test. We then conduct-
ed a gender–specific meta–analysis to estimate prevalence 
and confidence intervals in men and women, using the 
DerSimonian–Laird method. In addition, box–and–whis-
kers plots of regional prevalence by gender were also pre-
sented (Online Supplementary Document). We also ex-
amined the difference in prevalence of RA between urban 
and rural populations. Since the RA prevalence is not nor-
mally distributed, we performed the non–parametric 
Mann-Whitney U test to test the null–hypothesis.
Figure 1. Flowchart presenting the literature search and the process of study selection (WoK = Web of Knowledge; 
G.H. = global health).
Figure 2. The relationship between mean and median preva-
lence of rheumatoid arthritis in low and middle–income 
countries in six WHO regions of the world.
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RESULTS
In our study, the majority of studies were from mainland 
China, with additional studies from Taiwan and Hong 
Kong. Mexico, Turkey, Iran, India, Pakistan, Philippines 
and Russia were also represented through multiple studies. 
The median year of publication was 2004, making the es-
timate useful for application to both the world population 
in 2000 and 2010. Twenty–one studies used the ARA cri-
teria, and all the remaining studies used the 1987 revised 
ACR criteria. Some studies had multiple cohorts. Each co-
hort was recognised separately during analysis, so that the 
final 48 studies resulted in 60 cohorts. In case of the Afri-
can region, only two studies were found from the entire 
region that fulfilled the criteria for inclusion. One of the 
studies had a very small sample size and did not find a sin-
gle case of RA, so it was excluded as uninformative. The 
other study had a crude prevalence rate of 1%, but we felt 
that it would be inadequate to base an entire regions' prev-
alence rate on a single study. Therefore, we decided to dis-
card both of those studies and replace them by Bowman’s 
systematic analysis in 2012 [20]. Bowman included all the 
studies ever conducted in Africa in his estimate, irrespec-
tive of the year of study, and the prevalence rate from his 
study was then applied to the population statistics of the 
region in 2000 and 2010.
When all studies were analysed in one large meta–analysis, 
irrespective of their heterogeneity, this resulted in an 
“LMIC” estimate for the prevalence of RA of 0.53% (95% 
CI: 0.45–0.61%). Analysis of heterogeneity confirmed that 
the data were highly heterogeneous (I2 = 96%) (Online 
Supplementary Document). We then studied the mean 
and median prevalence in each of the six WHO regions 
(Figure 2) and presented box–and–whiskers plot of the 
results from studies in each region (Figure 3). The Kruskal-
Wallis one–way analysis of variance by ranks test showed 
that the prevalence in at least one of the WHO regions was 
statistically different from the others (P = 0.029).
A series of region–specific meta–analyses were conducted 
to estimate regional prevalence of RA. The meta–analysis 
estimates of regional RA prevalence rates were 0.40% (95% 
CI: 0.23–0.57%) for Southeast Asia, 0.37% (95% CI: 0.23–
0.51%) for Eastern Mediterranean, 0.62% (95% CI: 0.47–
0.77%) for European LMIC countries, 1.25% (95% CI: 
0.64–1.86%) for American LMIC countries and 0.42% 
(95% CI: 0.30–0.53%) for Western Pacific LMIC countries, 
respectively. This analysis could not be performed for Af-
rica due to limited data. The data sets were heterogeneous 
in all the regions (I2 varied from 74.2% to 97.3%).
We then studied whether the mean age of the sample con-
tributed to the observed prevalence rates. Linear correla-
tion coefficients (Pearson, Kendall’s tau, and Spearman) 
and the generalised dependence measure mutual informa-
tion did not show an effect of mean age of the sample on 
the reported prevalence of RA across the studies (P = 0.0599; 
P > 0.05), implying that the differences in age structure of 
samples in different studies were not the main determinant 
of the observed heterogeneity.
An investigation into differences in prevalence by gender 
using paired samples t–test indicated that the male and fe-
male RA prevalence differed significantly (P < 0.0001), 
which was expected. We therefore conducted a separate 
meta–analysis of the RA prevalence in LMIC countries for 
men and women. Male prevalence was 0.16% (95% CI: 
0.11–0.20%) (Figure 4) while the prevalence in women 
was five times higher, amounting to 0.75% (95% CI: 0.60–
0.90%) (Figure 5). Data seemed to be less heterogeneous 
for men (I2 = 49.6%) than for women (I2 = 83.7%).
We also examined the difference in prevalence of RA be-
tween urban and rural populations, wherever information 
was available to allow for comparison. Since we established 
that the RA prevalence was not normally distributed, we 
performed the non–parametric Mann-Whitney U test to 
test the null hypothesis. The significance of the test was 
P = 0.353, indicating that the prevalence in the urban and 
rural settings do not differ significantly (Figure 6).
After all the previous analyses, a strategy was needed for 
estimating the number of persons living with RA in LMIC 
in the years 2000 and 2010. Possible approaches were: (i) 
to apply the meta–analysis of the crude prevalence from all 
identified studies to the total number of persons 15 years 
or older in LMIC; (ii) to use the estimate of prevalence for 
males and for females that resulted from the meta–analyses 
of all studies that reported the rates separately by gender; 
Figure 3. Regional median, minimum and maximum observed 
value and inter–quartile range for the prevalence of rheumatoid 
arthritis in low and middle–income countries in six WHO 
regions of the world.
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then, to apply those two estimates of prevalence to male 
and female populations in LMIC; (iii) to use regional me-
dians or the estimates based on regional meta–analysis and 
apply them to the regional populations aged 15 years or 
older; (iv) finally, to use sex–specific regional estimates and 
apply it to male and female population aged 15 years or 
older in respective regions.
Given the quantity and quality of the information that was 
obtained through this systematic review, the most appro-
priate (and robust) approach was to use gender–specific 
estimates of prevalence for the whole LMIC region and ap-
ply them to male and female populations in LMIC. There 
are a number of reasons why other approaches were not 
preferred and we will list them here. Although the quan-
tity of information was the largest for the approach (i) 
above, there is uncertainty in some studies over the com-
position of sample by gender, and whether it is representa-
tive of the underlying population. Given that gender is an 
extremely important determinant of prevalence, the ap-
proach (i) would suffer from a possible confounding effect 
of the gender composition of the sample. The strength of 
approach (iii) was that it could account for regional varia-
tion. However, the number of studies typically available for 
different regions was simply too small to be sure whether 
the observed differences between regions were real, or just 
stochastic. The same applies to approach (iv). Therefore, 
approach (ii) was used, because it accounted for the most 
important confounding variable – gender – and because it 
provided a lot of information for meta–analysis in each gen-
der. This allowed an assumption that the rates considered 
representative for all males and all females in LMIC were 
more likely to be accurate than region–specific rates. More-
over, the observed heterogeneity of the underlying data was 
the lowest in gender–specific meta–analysis across LMIC.
This gives an estimate of male prevalence of 0.156% (95% 
CI: 0.11–0.20%) (Figure 4) that needs to be applied to the 
male population aged 15 years or more in LMIC in 2000 and 
2010. In females, the prevalence of 0.747% (95% CI: 0.60–
0.90%) is used (Figure 5). The UN Population Division's 
estimates for the number of males aged 15 years or older in 
LMIC in the year 2000 is 1.667 billion, and in the year 2010 
it is 2.206 billion [17]. For women, the corresponding fig-
ures are 1.634 billion for the year 2000 and 1.991 billion in 
2010 [17]. This translates into 2.60 (95% CI: 1.85–3.34%) 
Figure 4. Meta–analysis of 
rheumatoid arthritis 
prevalence in men, based on 
all available information from 
low and middle–income 
countries in six WHO regions 
of the world.
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million male sufferers and 12.21 (95% CI: 9.78–14.67%) 
million female sufferers in the year 2000, and 3.16 (95% CI: 
2.25–4.05%) million affected males and 14.87 (95% CI: 
11.91–17.86%) million affected females in the year 2010 in 
the countries of low and middle income.
DISCUSSION
We presented a robust estimate of the number of individu-
als suffering from RA in low and middle income countries 
in 2000 and 2010. There have already been several at-
tempts to estimate the prevalence of RA at the global, re-
gional and national level and also in LMIC [10,11,14,18,19]. 
In comparison to previous estimates that presented both 
higher and lower estimates than our study, our estimate is 
based primarily on a substantial amount of evidence from 
LMIC on sex–specific prevalence. We demonstrated that 
gender is a principal determinant of RA in LMIC and that 
age distribution of the population and being an urban 
dweller do not contribute significantly to disease develop-
ment. This is different from some other diseases, such as 
dementia and cancer, where age seems to be the main de-
Figure 5. Meta–analysis of 
rheumatoid arthritis preva-
lence in women, based on all 
available information from low 
and middle–income countries 
in six WHO regions of the 
world.
Figure 6. A scatterplot of observed prevalence rates of rheuma-
toid arthritis in six WHO regions based on urban or rural 
residency of the examinees. No statistical differences were noted 
(see Online Supplementary Document for further detail).
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terminant, or schizophrenia, where being an urban dwell-
er and family history seem to be the main driver of the dis-
ease occurrence [1,2]. Therefore, we believe that our 
strategy for deriving the estimate was more appropriate 
than used in some previous studies. Moreover, we provide 
the full data set used to develop the estimates in Online 
Supplementary Document and all our methods are trans-
parent and replicable by other groups.
Still, there are limitations in all estimates of the current 
global burden of RA. The criteria of defining the disease 
have changed over time and the estimates that don't take 
this into account will be internally inconsistent. Moreover, 
a mixture of studies, both hospital and population based 
studies, could be considered, although the former will pres-
ent the more severe end of disease spectrum and bias the 
results. A major strength of our study is that it made use of 
all literature available in all languages, including two major 
Chinese databases and the database with grey literature. 
We therefore believe that we are presenting the most ad-
vanced estimate of RA burden to date. However, limitations 
are still large: there are very few data points (particularly in 
Africa) and most LMIC countries do not have a single pub-
lished epidemiological study. Moreover, most of the studies 
used for this estimate are quite small and they are unlikely 
to be nationally representative. Also, this study uses a wide 
range of years to provide estimates for 2000 and 2010, 
which is a limitation given that prevalence may be chang-
ing over time and that the time trend reported here arises 
from demographic changes, rather than our understanding 
of the epidemiological situation.
Our paper also aimed to explore whether other major co-
variates, besides gender, affect the frequency of the occur-
rence of RA. We were unable to demonstrate significant ef-
fects for either urban / rural living or age structure of the 
study sample. Comparing all urban, rural and mixed stud-
ies amongst each other, we were unable to demonstrate sig-
nificant differences between prevalence rates in urban or 
rural areas. This is contrary to some previous reports that 
suggested that the prevalence might be higher in urban ar-
eas [21]. Moreover, previous reports suggested that the 
prevalence rate in LMIC is lower than in the developed 
countries [22], which our study seems to generally support.
One of the major strengths of our study is that it involved 
a systematic search of ten large databases, resulting in the 
identification of 10 599 studies initially and 48 studies se-
lected for inclusion. Native speakers translated studies in a 
language other than English, specifically Chinese and 
Spanish. This has greatly increased the pool of studies avail-
able for analysis, as it led to the inclusion of studies other-
wise excluded due to language barriers. All of the studies 
used the same definition to identify RA in patients: the 
1987 revised ACR criteria (previously known as ARA cri-
teria). This enabled comparison and convergence of stud-
ies towards a single plausible estimate. Besides three stud-
ies, in which we adjusted the estimate, all others determined 
the prevalence rate using the same age cut–off (15 years or 
older), again leading to comparable estimates underlying 
each regional and the overall prevalence rate.
Although the best quality of epidemiological work on RA 
in LMIC has been conducted by WHO–ILAR–COPCORD 
[23], this program covers a limited number of countries 
and this current review includes a larger number of studies 
conducted elsewhere, by different researchers, leading to 
wider coverage. Still, nearly all of the retained studies close-
ly followed the three–step methodology set by WHO–
ILAR–COPCORD and used similar questionnaires, thereby 
decreasing the methodological variability in the studies 
[23]. The questionnaires were translated in local languages 
and tested before the start of the studies in almost all cases.
Nevertheless, variation remained even within the selected 
studies that share the same three–step methodology. The 
assessors at each stage were different between the studies. 
In some studies, trained nurses administered the question-
naire, while in others this was done by trained volunteers 
and students. At the second and third stage most studies 
involved rheumatologists, but a handful of studies had gen-
eral medical doctors or internists evaluate the potential cas-
es. Moreover, among the studies conducted by COPCORD, 
there was a slight regional variation in the questionnaire 
used, given that it was modified over time, decreasing the 
comparability of studies. Although the number of partici-
pants at each step is given, the reason of non–participation 
is not stated in all studies. This may have led to non–re-
spondent bias. Although this problem cannot be easily con-
trolled, it still needs to be acknowledged, as there may be 
a difference in characteristics of those who participate and 
those who do not.
Research in developed countries does not seem to suggest 
a growing trend in the prevalence of the disease. However, 
the total number of cases grew considerably between 2000 
and 2010 because the population of LMIC older than 15 
years has grown in this period [24]. Even a slight increase 
in the prevalence rate, eg, an additional prevalence of 0.1%, 
would translate to an increment of 4 million affected per-
sons. Given the fact that RA affects the working age popu-
lation and most of the employment in these countries is 
still for manual labour, it greatly decreases the productivity 
of countries as a whole [25]. Additionally, the high costs of 
treatment, borne by individuals themselves in the most 
LMIC, counters other efforts to decrease poverty and im-
prove living standards.
As RA is an important condition with significant morbid-
ity and economic impact, it should be at the forefront in 
health care policy. Despite this, RA as part of a larger group 
of NCD receives less than 3% of annual development as-
sistance for health to low and middle income countries. 
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The neglect of NCD on the global stage can be explained 
not only by the gaps in estimates on burden of disease but 
also from a lack of strategic communication about the ur-
gency of the problem [26].
In this paper, estimates of RA morbidity aim to take a first 
step in raising awareness of policy makers and health care 
workers, as previously they have had to rely on the evi-
dence that was generated mainly in the developed world. 
The lack of specialists to diagnose and treat this condition 
should also be addressed. In certain African nations there 
is only one rheumatologist for the entire population [21]. 
Therefore, an increase in the number of specialists in this 
area is urgently needed in LMIC [27]. As this takes time, the 
existing doctors in the community should be offered spe-
cific education on RA, including newer treatment regimens 
and the management of the associated comorbid conditions. 
As most of the population resides in rural areas, incorporat-
ing identification and treatment of the disease in commu-
nity health care system is crucial to reach all those in need 
of diagnosis and treatment. Funding should be targeted at 
increasing efficacy of treatments in LMIC. Efforts should be 
made to increase the availability of treatment – both anti–
inflammatories and the newer biological agents that have 
proven to be greatly beneficial – at affordable costs. The 
newer biological agents are very expensive and it is unlike-
ly that many LMIC could afford to supply them [25]. More-
over, RA is associated with an increased risk of other dis-
eases (such as cardiovascular diseases) and the management 
of these comorbid conditions is also important. All doctors 
should be made aware of treatment protocols already in use 
by high–income countries with emphasis on early treat-
ment, to slow disease progression and elimination of pain. 
This should lead to improvements in quality of life and de-
crease the occurrence of co–morbid conditions, such as de-
pression. The set–up of supportive treatment, such as phys-
iotherapy, should be encouraged [11–18].
Infrastructure for research in areas where it is currently un-
available should be set up. Allegiance with international 
agencies already working towards generating information, 
such as WHO–ILAR [23], should be undertaken and their 
efforts should be supported. In Africa, the African League 
of Associations of Rheumatology (AFLAR) already exists, 
but little has been done in terms of research and surveil-
lance of rheumatologic diseases [20]. Such associations 
should be supported, encouraged and pressurised by gov-
ernments to carry on more work in this area. The WHO–
ILAR–COPCORD program was developed to identify all 
types of musculoskeletal disorders, and not specifically de-
signed for rheumatoid arthritis nor as an epidemiological 
study program [23]. Therefore, further research should be 
specifically orientated towards rheumatoid arthritis, with 
greater attention on the methodology. The lack of informa-
tion from more than 100 LMIC countries should be ad-
dressed and gaps filled. Studies should also include age 
groups of those with the disorder, thereby providing more 
information on who bears the greatest burden and allow-
ing age–standardised comparison. Simultaneously, infor-
mation about risk factors should be obtained and incorpo-
rated in study designs. 
The estimates presented in this paper provide a building 
block for future epidemiological studies by suggesting the 
way forward in disease assessment in LMIC context and 
the methodology that could be deployed. It could also be 
used to create awareness among health–care workers and 
education of people about the disease and encourage 
health–seeking behaviour for provision of available treat-
ment, which can decrease the burden associated with dis-
ability and bring about a decrease in morbidity. It is also 
noteworthy to point out the reoccurring theme of lack of 
data from the poorest countries. Policy makers from these 
countries should show more dedication and step up their 
efforts towards research in the health care sector, as gener-
ating information about the burden of disease is the first 
step in decreasing its prevalence.
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